NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Foghorn Therapeutics Inc. (FHTX) Stock Analysis

Foghorn Therapeutics Inc. (FHTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

FHTX

$2.04

+$0.03 (+1.49%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FHTX with… →

FHTX Key Statistics

As of Oct 21, 2026
Trading
Open
$2.02
Previous Close
$2.01
Day's Range
1.99–2.10
52-Week Range
1.79–7.61
Volume
819.59K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.01
Valuation
Market Cap
$121.15M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.30
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.98
Financials (FY)
Revenue (FY)
$30.91M+36.75%
Net Income (FY)
−$74.28M
Profit marginThe share of revenue left as profit after all costs and taxes.
−175.78%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
59.39M
1-Year Return
−49.88%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
678.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, FHTX closed at $2.04, −49.88% over 1 year.

Foghorn Therapeutics Inc. (FHTX) has a market capitalization of $121.15M.

In fiscal 2025, FHTX reported revenue of $30.91M.

FHTX Stock Return by Calendar Year

Foghorn Therapeutics Inc. (FHTX) return since Oct 2020: what $10,000 became

1 year
$10,000 $5,012
−49.88%
5 years
$10,000 $1,646
−83.54%
Since Oct 2020
$10,000 $1,126
−88.74%

If you had invested $10,000 in Foghorn Therapeutics Inc. (FHTX) at the close on October 23, 2020, the earliest close on record here, it would have been worth $1,126 at the close on October 21, 2026: −88.74% in total, −30.54% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−62.22%
2025+14.41%
2024−26.82%
2023+1.10%
2022−72.10%
2021+12.83%
2020 (partial year)+11.87%

As of October 21, 2026.

FHTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$30.91M−$74.28M−240.3%
2024$22.60M−$86.62M−383.2%
2023$34.16M−$98.43M−288.2%
2022$19.23M−$108.88M−566.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$30.91M—−$82.11M−$74.28M−240.3%
2024$22.60M—−$100.29M−$86.62M−383.2%
2023$34.16M—−$107.91M−$98.43M−288.2%
2022$19.23M—−$117.14M−$108.88M−566.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FHTX Valuation vs Biotechnology Median

Median of 608 stocks
MetricFHTXBiotechnology medianvs median
P/S ratio3.3013.300.2x the median
Profit margin−175.78%−38.31%137.5 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Foghorn Therapeutics Inc. (FHTX) carries a market capitalisation of $121.15M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 106 employees.

The most recent close on file for FHTX is $2.04, dated October 21, 2026. That is +$0.03 (+1.49%) against the previous close. The 52-week range on file runs from $1.79 to $7.61. The latest close sits 13.97% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $30.91M. That is +36.75% against the prior fiscal year, when revenue was $22.60M. The same year closed with a net loss of $74.28M. Profit margin runs at −175.78%. That is 137.5 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.98.

Across the 4 fiscal years on file, revenue moves from $19.23M in 2022 to $30.91M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 3.3 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 3.01. Daily returns over the trailing 6 years annualize to a volatility of 92.24%. The trailing one-year total return is −49.88%. Measured over 5 years, that is −30.29% a year compounded.

Growth & Income

The record shows no dividend for FHTX.

Across the complete calendar years on file, 2025 returned +14.41% and 2022 returned −72.10%. Of the 5 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −62.22% year to date.

Peer Comparison

Foghorn Therapeutics Inc. (FHTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Foghorn Therapeutics Inc. FHTX $121.15M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Foghorn Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Visit website →